Autopsy report · NCT01242514
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Cause of deathFunding or business
“AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.”
Life of this trial
- Registered 2 months before it started.
- Ran for about 4 years before it stopped.
- 1,917 participants enrolled.
- Results were posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Conditions
- Rheumatoid Arthritis
- Interventions
- Fostamatinib; Fostamatinib; Fostamatinib
- Participants
- 1,917
- Sites
- 308
- Countries
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Estonia, France, Germany and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.